Cargando…
In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer
BACKGROUND: Epigenomic dysregulation has been linked to solid tumour malignancies, including ovarian cancers. Profiling of re-programmed enhancer locations associated with disease has the potential to improve stratification and thus therapeutic choices. Ovarian cancers are subdivided into histologic...
Autores principales: | Quintela, Marcos, James, David W., Garcia, Jetzabel, Edwards, Kadie, Margarit, Lavinia, Das, Nagindra, Lutchman-Singh, Kerryn, Beynon, Amy L., Rioja, Inmaculada, Prinjha, Rab K., Harker, Nicola R., Gonzalez, Deyarina, Steven Conlan, R., Francis, Lewis W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307814/ https://www.ncbi.nlm.nih.gov/pubmed/37120667 http://dx.doi.org/10.1038/s41416-023-02274-2 |
Ejemplares similares
-
Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells
por: Quintela, Marcos, et al.
Publicado: (2023) -
Delayed endometrial decidualisation in polycystic ovary syndrome; the role of AR-MAGEA11
por: Younas, Kinza, et al.
Publicado: (2019) -
ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance
por: Löschmann, Nadine, et al.
Publicado: (2016) -
Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer
por: Howard, David, et al.
Publicado: (2022) -
Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer
por: Howard, David, et al.
Publicado: (2021)